Maximizing endogenous β-cell regeneration

Current Opinion in Organ Transplantation

Volumn 12, Issue 1, 2007, Pages 55-62

  Crutchlow, Michael F ^a   Stoffers, Doris A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cell cycle; Exendin 4; Islet; Proliferation

Indexed keywords

DACLIZUMAB; EPIDERMAL GROWTH FACTOR; EXENDIN 4; GASTRIN; GLUCAGON LIKE PEPTIDE 1; IMMUNOMODULATING AGENT; LISOFYLLINE;

CELL CYCLE; CELL MATURATION; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CELL VIABILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MITOGENICITY; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REGENERATIVE ABILITY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

EID: 33846266612     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328012b281     Document Type: Review

References (43)

1. Bonner-Weir S. Perspective: Postnatal pancreatic beta cell growth. Endocrinology 2000; 141:1926-1929.
2. Meier JJ, Bhushan A, Butler AE, et al. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005; 48:2221-2228. This paper describes the persistence of β-cells in the pancreas of individuals with type 1 diabetes despite ongong auto-immunity and accelerated β-cell death, providing indirect evidence of ongoing new β-cell production.
3. Meier JJ, Lin JC, Butler AE, et al. Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. Diabetologia 2006; 49:1838-1844. This is a case report describing accelerated β-cell proliferation in the setting of new onset autoimmune diabetes in an elderly man, demonstrating that human β-cells may retain proliferative potential throughout adulthood.
4. •]) demonstrating that immune modulation with Freund's complete adjuvant and euglycemia achieved through islet transplantation resulted in recovery of endogenous insulin production in a minority of NOD mice. These studies demonstrated that immune modulation and euglycemia may provide a permissive environment for β-cell regeneration.
5. Suri A, Calderon B, Esparza TJ, et al. Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science 2006; 311:1778-1780. These studies demonstrated that immune modulation and euglycemia may provide a permissive environment for β-cell regeneration.
6. Chong AS, Shen J, Tao J, et al. Reversal of diabetes in nonobese diabetic mice without spleen cell-derived beta cell regeneration. Science 2006; 311:1774-1775. These studies demonstrated that immune modulation and euglycemia may provide a permissive environment for β-cell regeneration.
7. Bonner-Weir S, Weir GC. New sources of pancreatic beta-cells. Nat Biotechnol 2005; 23:857-861.
8. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004; 429:41-46.
9. Heit JJ, Karnik SK, Kim SK. Intrinsic regulators of pancreatic beta-cell proliferation. Annu Rev Cell Dev Biol 2005.
10. Georgia S, Bhushan A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. J Clin Invest 2004; 114:963-968.
11. Kushner JA, Ciemerych MA, Sicinska E, et al. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol 2005; 25:3752-3762.
12. Rane SG, Dubus P, Mettus RV, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999; 22:44-52.
13. Cozar-Castellano I, Weinstock M, Haught M, et al. Evaluation of beta-cell replication in mice transgenic for hepatocyte growth factor and placental lactogen: comprehensive characterization of the G1/S regulatory proteins reveals unique involvement of p21cip. Diabetes 2006; 55:70-77. This study demonstrated β-cell p21 upregulation in the setting of trophic stimulation and enhanced β-cell response to mitogenic stimulation in the absence of p21, suggesting that CKI upregulation may be an inherent brake on proliferation.
14. Uchida T, Nakamura T, Hashimoto N, et al. Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. Nat Med 2005; 11:175-182.
15. Hashimoto N, Kido Y, Uchida T, et al. Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet 2006; 38:589-593. This study demonstrated postnatal β-cell failure resulting from PDK-1 deletion. Beta-cell failure was associated with diminished signaling downstream of PDK-1 and largely reversed by FOXO-1 haplo-insufficiency. These findings suggest a critical role for PDK-1 in the β-cell and that FOXO-1 mediates β-cell failure in this setting.
16. Fatrai S, Elghazi L, Balcazar N, et al. Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. Diabetes 2006; 55:318-325. This study demonstrated downstream events in the setting of constitutive β-cell AKT activation including GSK-3β and FOXO-1 phosphorylation, increased D-cyclin expression and increased CDK-4 activity. Further, p21 expression was increased, supporting its role as a molecular brake on proliferation.
17. Karnik SK, Hughes CM, Gu X, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A 2005; 102:14659-14664. MEN1 haplo-insufficiency results in increased β-cell proliferation in association with decreased expression of the CKIs, p18 and p27, associated with decreased menin-mediated methylation of critical promoter elements. This study demonstrated a role for menin in the regulation of β-cell proliferation, and suggested an underlying epigenetic mechanism.
18. Schnepp RW, Chen YX, Wang H, et al. Mutation of tumor suppressor gene Men1 acutely enhances proliferation of pancreatic islet cells. Cancer Res 2006; 66:5707-5715. This study demonstrated that conditional MEN1 deletion acutely increases islet cell proliferation in association with p18 and p27 loss, indicating its role in islet cell cycle regulation.
19. Park S, Dong X, Fisher TL, et al. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 2006; 281:1159-1168. This study demonstrated that exendin-4 treatment increases IRS-2 expression and signaling downstream of IRS-2 in rodent and human β-cells and that exendin-4 does not preserve β-cell mass in IRS-2 null mice, suggesting that the trophic actions of exendin-4 are IRS-2 dependent.
20. Stoffers DA. The development of beta-cell mass: recent progress and potential role of GLP-1. Horm Metab Res 2004; 36 (11-12):811-821.
21. Vasavada RC, Gonzalez-Pertusa JA, Fujinaka Y, et al. Growth factors and beta cell replication. Int J Biochem Cell Biol 2006; 38 (5-6):931-950.
22. Elghazi L, Balcazar N, Bernal-Mizrachi E. Emerging role of protein kinase B/Akt signaling in pancreatic beta-cell mass and function. Int J Biochem Cell Biol 2006; 38:157-163.
23. Otani K, Kulkarni RN, Baldwin AC, et al. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. Am J Physiol Endocrinol Metab 2004; 286:E41-E49.
24. Kulkarni RN, Bruning JC, Winnay JN, et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96:329-339.
25. Kulkarni RN, Holzenberger M, Shih DQ, et al. Beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet 2002; 31:111-115.
26. Xuan S, Kitamura T, Nakae J, et al. Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 2002; 110:1011-1019.
27. Ueki K, Okada T, Hu J, et al. Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet 2006; 38:583-588. This study demonstrated postnatal β-cell failure and diabetes in mice with combined selective β-cell deletion of both the insulin and insulin-like growth factor-1 receptors, confirming the importance of their shared signaling pathway in the β-cell.
28. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391:900-904.
29. Lingohr MK, Briaud I, Dickson LM, et al. Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet beta-cells. J Biol Chem 2006; 281:15884-15892. This study demonstrated that glucose regulates IRS-2 expression at the transcriptional level in a calcium dependent process. This suggests that changes in IRS-2 expression may be important for β-cell adaptation to metabolic cues.
30. Hennige AM, Ozcan U, Okada T, et al. Alterations in growth and apoptosis of insulin receptor substrate-1-deficient beta-cells. Am J Physiol Endocrinol Metab 2005; 289:E337-E346.
31. Jhala US, Canettieri G, Screaton RA, et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 2003; 17:1575-1580.
32. Screaton RA, Conkright MD, Katoh Y, et al. The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell 2004; 119:61-74.
33. Kushner JA, Simpson L, Wartschow LM, et al. Phosphatase and tensin homolog regulation of islet growth and glucose homeostasis. J Biol Chem 2005; 280:39388-39393. This study demonstrated the suppressive role of Pten downstream of IRS-2 in β-cells by showing that Pten haplo-insufficiency preserves islet growth and functionin IRS-2 null mice and promotes signaling in the insulin receptor/insulin-like growth factor receptor pathway.
34. Stiles BL, Kuralwalla-Martinez C, Guo W, et al. Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol 2006; 26:2772-2781. This study demonstrated that β-cell specific Pten deletion resulted in decreased β-cell death and increased proliferation, indicating a suppressive role for Pten in β-cell growth and viability.
35. Kitamura T, Nakae J, Kitamura Y, et al. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 2002; 110:1839-1847.
36. Okamoto H, Hribal ML, Lin HV, et al. Role of the forkhead protein FOXO1 in beta cell compensation to insulin resistance. J Clin Invest 2006; 116:775-782.
37. Martinez SC, Cras-Meneur C, Bernal-Mizrachi E, Permutt MA. Glucose regulates Foxo1 through insulin receptor signaling in the pancreatic islet β-cell. Diabetes 2006; 55:1581-1591. This study demonstrated that hyperglycemia produced insulin receptor dependent phosphorylation/nuclear exclusion of FOXO-1 in cultured mouse β-cells, suggesting that this may be an important autocrine/paracrine trophic action of secreted insulin.
38. Buteau J, Spatz ML, Accili D. Transcription factor FOXO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 2006; 55:1190-1196. Using in-vitro and murine models, this study demonstrated that GLP-1 stimulation increases FOXO-1 phosphorylation/inactivation, and that constitutively active FOXO-1 blocks the beneficial effects of exendin-4 on β-cell growth and viability.
39. Johnson JD, Ahmed NT, Luciani DS, et al. Increased islet apoptosis in Pdx1+/- mice. J Clin Invest 2003; 111:1147-1160.
40. Kops GJ, Medema RH, Glassford J, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 2002; 22:2025-2036.
41. Schmidt M, Fernandez de Mattos S, van der Horst A, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 2002; 22:7842-7852.
42. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003; 2:339-345.
43. Okamoto H. The Reg gene family and Reg proteins: with special attention to the regeneration of pancreatic beta-cells. J Hepatobiliary Pancreat Surg 1999; 6:254-262.